A Rare Case of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is an extremely rare variant of adult non-Hodgkin lymphomas accounting for less than 2 % of all Т-cell tumors. This disease is characterized by a very aggressive course. The overall survival of patients within 12 months after the diagnosis does not exceed 36 %. Currently, there are no standards for MEITL therapy. All plausible treatment approaches are described in very few case reports. The usual practice is to apply induction therapy regimens which are effective against the most of aggressive T-cell tumors. If stable response is achieved, patients receive high-dose chemotherapy with autologous hematopoietic stem cell transplantation. MEITL patients rather often develop various life-threatening and surgery-requiring complications. The present paper describes a case of a 50-year-old patient with MEITL. The disease was diagnosed on the basis of the immunomorphological analysis of gastric and colon mucosa biopsies. The first-line therapy consisted of 4 BV-CHEP/BV-CHP (cyclophosphamide, etoposide, doxorubicin, prednisolone, and brentuximab vedotin) cycles. The tumor progression with the development of decompensated pyloric stenosis was revealed. Laparoscopic gastroenteroanastomosis was provided. The second-line therapy included ruxolitinib and lenalidomide. The optimal combination of medication and surgery achieved the success in persistent stabilization of tumor with a satisfactory quality of life being maintained. The rarity of the disease, poor prognosis, common surgery complications, and lack of unified therapy standards raise the practical value and urgency of every single case report. MEITL patient management calls for an effective interdisciplinary interaction with personalized approach to treatment decision making in each specific clinical situation.

• Anastasiya Gennadevna Kolgotina NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0009-0001-2174-9083 (unauthenticated)
• L.A. Kramynin NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0003-4542-8353 (unauthenticated)
• I.V. Ishmatova NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0009-0004-2898-9823 (unauthenticated)
• L.V. Filatova NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0002-0728-4582 (unauthenticated)
• P.A. Sapronov NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0009-0004-5122-8192 (unauthenticated)
• M.V. Grinkevich NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0002-0538-7369 (unauthenticated)
• A.L. Muravtseva NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758; AM Granov Russian Research Center for Radiology and Surgical Technologies, 70 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0002-4221-4248 (unauthenticated)
• I.S. Zyuzgin NN Petrov National Medical Cancer Research Center, 68 Leningradskaya ul., pos. Pesochnyi, Saint Petersburg, Russian Federation, 197758 https://orcid.org/0000-0001-9597-4593 (unauthenticated)

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. doi: 10.1182/blood-2016-01-643569. DOI: https://doi.org/10.1182/blood-2016-01-643569
2. Huang D, Lim JQ, Cheah DMZ, et al. Whole-genome sequencing reveals potent therapeutic strategy for monomorphic epitheliotropic intestinal T-cell lymphoma. Blood Advances. 2020;4(19):4769–74. doi: 10.1182/bloodadvances.2020001782. DOI: https://doi.org/10.1182/bloodadvances.2020001782
3. Nairismägi ML, Tan J, Lim JQ, et al. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia 2016;30(6):1311–9. doi: 10.1038/leu.2016.13. DOI: https://doi.org/10.1038/leu.2016.13
4. Nicolae A, Xi L, Pham TH, et al. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. Leukemia. 2016;30(11):2245–7. doi: 10.1038/leu.2016.178. DOI: https://doi.org/10.1038/leu.2016.178
5. Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602. doi: 10.1038/ncomms12602. DOI: https://doi.org/10.1038/ncomms12602
6. Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol. 2012;87(7):663–8. doi: 10.1002/ajh.23213. DOI: https://doi.org/10.1002/ajh.23213
7. Veloza L, Cavalieri D, Missiaglia E, et al. Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome. Haematologica. 2023;108(1):181–95. doi: 10.3324/haematol.2022.281226. DOI: https://doi.org/10.3324/haematol.2022.281226
8. Van Vliet C, Spagnolo DV. T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update. Pathology. 2020;52(1):128–41. doi: 10.1016/j.pathol.2019.10.001. DOI: https://doi.org/10.1016/j.pathol.2019.10.001
9. Tuffaha MSA, Guski H, Kristiansen G. Immunohistochemistry in tumor diagnostics. Springer; 2018. рр. 166–72. doi: 10.1007/978-3-319-53577-7. DOI: https://doi.org/10.1007/978-3-319-53577-7
10. Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35(10):1557–69. doi: 10.1097/PAS.0b013e318222dfcd. DOI: https://doi.org/10.1097/PAS.0b013e318222dfcd
11. Yi JH, Lee GW, Do YR, et al. Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. Ann Hematol. 2019;98(11):2541–50. doi: 10.1007/s00277-019-03791-y. DOI: https://doi.org/10.1007/s00277-019-03791-y
12. Horwitz S, O’Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288–98. doi: 10.1016/j.annonc.2021.12.002. DOI: https://doi.org/10.1016/j.annonc.2021.12.002
13. Brink M, Meeuwes FO, van der Poel MWM, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022;140(9):1009–19. doi: 10.1182/blood.2021015114. DOI: https://doi.org/10.1182/blood.2021015114
14. Iyer SP, Jagadeesh D, Domenech ED, et al. Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study. J Clin Oncol. 2024;42(16_suppl):7069. doi: 10.1200/JCO.2024.42.16_suppl.7069. DOI: https://doi.org/10.1200/JCO.2024.42.16_suppl.7069
15. Karube K, Kakimoto Y, Tonozuka Y, Ohshima K. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Rev Hematol. 2021;14(8):777–87. doi: 10.1080/17474086.2021.1955344. DOI: https://doi.org/10.1080/17474086.2021.1955344
16. Sotomayor EM, Young KH, Younes A. Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy. Clin Adv Hematol Oncol. 2014;12(4 Suppl 10):1–22.
17. NCCN Guidelines Version 1.2025. T-Cell Lymphomas. Available from: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf (accessed 17.01.2025).
18. Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828–37. doi: 10.1182/blood.2021013379. DOI: https://doi.org/10.1182/blood.2021013379
19. Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716–23. doi: 10.1002/cncr.29103. DOI: https://doi.org/10.1002/cncr.29103
20. Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860–3. doi: 10.1093/annonc/mdp508. DOI: https://doi.org/10.1093/annonc/mdp508
21. McKinney M, Moffitt AB, Gaulard P, et al. The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discov. 2017;7(4):369–79. doi: 10.1158/2159-8290.CD-16-0330. DOI: https://doi.org/10.1158/2159-8290.CD-16-0330